Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb chooses UCLA as latest research partner

December 14, 2015
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …

News
Ablynx CEO Edwin Moses

Ablynx sets focus on pharma collaborations

December 14, 2015
Manufacturing and Production, Research and Development Ablynx, collaboration, nanobodies, partnership

Drug development companies should prioritise strategic pharma collaborations to keep up with the next wave of immuno-oncology treatments, the chief …

News
personal-95715_640

Mirror. Signal. Merger. How to deal with a pharma takeover

December 14, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers

So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …

Feature
AZ building

AstraZeneca in $5bn Acerta buyout talks

December 14, 2015
Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …

News
Chest x ray

Roche lung cancer drug Alecensa gets rapid US approval

December 14, 2015
Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer

The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …

News
Novartis image

Novartis earns provisional NICE yes for Entresto

December 11, 2015
Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure

NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …

News
labcorps_purchase_of_covance_topped_the_outsourcing_deals_in_2015

M&A activity drives record year for pharma outsourcing deals

December 11, 2015
Sales and Marketing Covance, M&A, MA, labcorp, outsourcing

A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …

News
halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015
Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …

News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015
Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …

News
roche_scientists

Which are pharma’s most innovative companies?

December 11, 2015
Medical Communications, Research and Development GSK, Roche, research and development

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …

Feature
AZ_scientist

AstraZeneca deal to delve into the secretome

December 11, 2015
Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …

News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015
Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …

News
xarelto

Regulators to probe Bayer’s Xarelto trial results

December 10, 2015
Medical Communications, Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …

News
Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015
Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …

News
Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015
Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …

News
cindy_whitehead

‘Female Viagra’ CEO leaves company

December 10, 2015
Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma

Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …

Appointment
Guido Rasi

EMA sets out new five-year plan

December 9, 2015
Research and Development EMA, Guido Rasi

The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …

News
MHRA

Early UK access for AstraZeneca lung cancer drug

December 9, 2015
AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib

UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …

News
Janssen image

Janssen submits Stelara for EU approval for Crohn’s

December 9, 2015
Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab

Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …

News
mackayjimeson_1345198498_140

Two new corporate affairs leads appointed at Pfizer

December 9, 2015
Medical Communications Pfizer, corporate affairs

Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads. The company recently restructured its global pharma business …

Appointment
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026